HFA
CRSP icon

HC Financial Advisors’s CRISPR Therapeutics CRSP Stock Holding History

HC Financial Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$15K Hold
250
– – 0.01% 206
2022
Q1 		$16K Hold
250
– – 0.01% 204
2021
Q4 		$19K Hold
250
– – 0.01% 204
2021
Q3 		$28K Buy
+250
New +$31.4K 0.02% 169

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

HC Financial Advisors's CRSP Position: Q2 2022 in Review

HC Financial Advisors held its CRISPR Therapeutics (CRSP) position steady in Q2 2022 at 250 shares worth $15K. The position accounts for 0.01% of the portfolio, ranked #206.

HC Financial Advisors first reported a position in CRSP in Q3 2021 and has held it in 4 quarters since. The position peaked at $28K in Q3 2021. 435 funds tracked by Wall St. Rank hold CRSP as of Q2 2022.

  • HC Financial Advisors held 250 shares of CRISPR Therapeutics worth $15K as of Q2 2022.
  • HC Financial Advisors left its CRISPR Therapeutics share count unchanged in Q2 2022.
  • CRISPR Therapeutics made up 0.01% of HC Financial Advisors's portfolio in Q2 2022, its #206 holding.
  • HC Financial Advisors first reported a position in CRISPR Therapeutics in Q3 2021 and has held it in 4 quarters since.
  • HC Financial Advisors's CRISPR Therapeutics position peaked at $28K in Q3 2021.
  • 435 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2022.

Based on HC Financial Advisors's 13F filing for Q2 2022, filed 25 Jul 2022.